BIP
AVDL

Brandes Investment Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Brandes Investment Partners’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-218,425
Closed -$4.71M – 188
2025
Q4 		$4.71M Sell
218,425
-5,226,378
-96% -$101M 0.04% 143
2025
Q3 		$83.1M Sell
5,444,803
-1,042,839
-16% -$13.6M 0.67% 55
2025
Q2 		$57.4M Buy
6,487,642
+820,467
+14% +$7.21M 0.52% 66
2025
Q1 		$44.4M Buy
5,667,175
+3,494,036
+161% +$29.3M 0.45% 74
2024
Q4 		$22.8M Buy
2,173,139
+798,415
+58% +$9.7M 0.26% 91
2024
Q3 		$18M Sell
1,374,724
-108,715
-7% -$1.66M 0.2% 94
2024
Q2 		$20.9M Buy
1,483,439
+21,214
+1% +$346K 0.26% 89
2024
Q1 		$24.7M Sell
1,462,225
-71,389
-5% -$1.06M 0.32% 80
2023
Q4 		$21.7M Buy
1,533,614
+84,842
+6% +$997K 0.33% 81
2023
Q3 		$14.9M Buy
1,448,772
+159,577
+12% +$2.14M 0.29% 83
2023
Q2 		$21.2M Sell
1,289,195
-155,440
-11% -$2.02M 0.43% 66
2023
Q1 		$13.2M Sell
1,444,635
-210,625
-13% -$1.73M 0.28% 82
2022
Q4 		$11.9M Sell
1,655,260
-1,044,535
-39% -$7.32M 0.33% 62
2022
Q3 		$13.5M Sell
2,699,795
-931,680
-26% -$5.13M 0.35% 73
2022
Q2 		$8.86M Buy
3,631,475
+642,800
+22% +$2.64M 0.22% 95
2022
Q1 		$20.4M Buy
2,988,675
+389,041
+15% +$2.67M 0.44% 63
2021
Q4 		$21M Sell
2,599,634
-647,652
-20% -$5.92M 0.46% 61
2021
Q3 		$31.8M Buy
3,247,286
+7,275
+0.2% +$57.3K 0.69% 50
2021
Q2 		$21.8M Buy
3,240,011
+305,770
+10% +$2.43M 0.48% 58
2021
Q1 		$26M Sell
2,934,241
-27,637
-0.9% -$223K 0.62% 51
2020
Q4 		$19.8M Buy
2,961,878
+121,209
+4% +$758K 0.51% 59
2020
Q3 		$14.3M Buy
2,840,669
+1,357,042
+91% +$9.87M 0.49% 58
2020
Q2 		$12M Sell
1,483,627
-155,211
-9% -$1.37M 0.36% 68
2020
Q1 		$13M Sell
1,638,838
-2,013,110
-55% -$15.5M 0.46% 63
2019
Q4 		$27.6M Sell
3,651,948
-2,530,888
-41% -$13.4M 0.66% 50
2019
Q3 		$25.7M Sell
6,182,836
-601,954
-9% -$1.51M 0.66% 52
2019
Q2 		$19.6M Sell
6,784,790
-267,930
-4% -$461K 0.44% 63
2019
Q1 		$10.2M Sell
7,052,720
-66,334
-0.9% -$150K 0.24% 74
2018
Q4 		$18.4M Buy
7,119,054
+783,506
+12% +$2.66M 0.47% 57
2018
Q3 		$27.8M Buy
6,335,548
+1,365,442
+27% +$7.37M 0.63% 46
2018
Q2 		$30.5M Buy
4,970,106
+161,613
+3% +$1.13M 0.69% 46
2018
Q1 		$35.1M Buy
4,808,493
+1,500,243
+45% +$13.2M 0.75% 44
2017
Q4 		$27.1M Buy
+3,308,250
New +$31M 0.55% 53

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Brandes Investment Partners's AVDL Position: Q1 2026 in Review

Brandes Investment Partners sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 218,425 shares — an estimated $4.71M sold.

Brandes Investment Partners first reported a position in AVDL in Q4 2017 and held it in 33 quarters. The position peaked at $83.1M in Q3 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Brandes Investment Partners reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Brandes Investment Partners sold 218,425 Avadel Pharmaceuticals shares in Q1 2026, an estimated $4.71M.
  • Brandes Investment Partners first reported a position in Avadel Pharmaceuticals in Q4 2017 and held it in 33 quarters.
  • Brandes Investment Partners's Avadel Pharmaceuticals position peaked at $83.1M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Brandes Investment Partners's 13F filing for Q1 2026, filed 15 May 2026.